Jacob van Naarden, Chief Business Officer at Loxo Oncology, Inc. (LOXO), sold 16,600 shares at $164.44 ($2.8M) on 2018-09-12, disclosed to the SEC on 2018-09-14.
Open-market sale of $2.8M LOXO by Chief Business Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $164.44 | 756 | $124K | 4.5% |
| 2 | $164.44 | 756 | $124K | 4.5% |
| 3 | $165.32 | 1,885 | $312K | 11.3% |
| 4 | $165.32 | 1,885 | $312K | 11.3% |
| 5 | $166.74 | 1,059 | $177K | 6.4% |
| 6 | $166.74 | 1,059 |
| $177K |
| 6.4% |
| 7 | $167.39 | 1,000 | $167K | 6.1% |
| 8 | $168.78 | 200 | $34K | 1.2% |
| 9 | $168.79 | 200 | $34K | 1.2% |
| 10 | $171.03 | 600 | $103K | 3.7% |
| 11 | $165.45 | 2,700 | $447K | 16.2% |
| 12 | $165.45 | 2,700 | $447K | 16.2% |
| 13 | $166.63 | 1,500 | $250K | 9.1% |
| 14 | $167.49 | 300 | $50K | 1.8% |
| Total | $166.03 avg | 16,600 | $2.8M | 100% |
| Filing → |
| LOXO | SELL | 2018-11-28 | $1.5M | — | Filing → |
| LOXO | SELL | 2018-10-05 | $2.0M | — | Filing → |
| LOXO | SELL | 2018-08-15 | $2.9M | — | Filing → |